

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Keratinocyte growth factor receptor (KGFR; FGFR2; CD332); tumor protein p63 (TP63; p63)	<p>Cell culture and mouse studies suggest inhibiting FGFR2 could help treat squamous cell carcinoma (SCC). In a newly developed mouse model of chemically induced SCC, p63-mediated induction of FGFR2 signaling was increased in tumors compared with normal skin, and the small molecule FGFR antagonist AZD4547 arrested tumor development and improved progression-free survival (PFS) compared with vehicle. Next steps include the identification of biomarkers to predict response to FGFR2-directed therapy in SCC.</p> <p>AstraZeneca plc's AZD4547 is in Phase II testing to treat various cancers. At least five companies have FGFR inhibitors in Phase II or earlier development to treat various cancers.</p> <p>SciBX 6(31); doi:10.1038/scibx.2013.820 Published online Aug. 15, 2013</p>	Unpatented; licensing not applicable	<p>Ramsey, M.R. <i>et al. J. Clin. Invest.</i>; published online July 8, 2013; doi:10.1172/JCI68899</p> <p>Contact: Leif W. Ellisen, Massachusetts General Hospital Cancer Center, Boston, Mass. e-mail: ellisen@helix.mgh.harvard.edu</p>